News Headlines
-
ProMed Pharma Acquires SpineThera Manufacturing Capabilities And An Option To License Intellectual Property
4/3/2024
SpineThera, Inc., a privately held, clinical-stage pharmaceutical company focused on the development of SX600 (a novel formulation of extended-release dexamethasone microspheres for epidural injection for the management of lumbar radicular pain) and ProMed Pharma LLC, a leading contract manufacturer of polymer-based drug releasing dosage forms and combination device components, announced today that ProMed Pharma has acquired SpineThera’s cGMP manufacturing operational assets.
-
Autolomous & BioCentriq Partner To Speed Up Cell Therapy Delivery
4/3/2024
Autolomous, the market-leading developer of critical manufacturing management systems for cell and gene therapies, and BioCentriq, industry-leading clinical-phase Cell Therapy CDMO (contract development and manufacturing organization), today announce a collaboration to digitize and accelerate process development and manufacturing activities.
-
Prozomix And Ginkgo Bioworks Collaborate On Next-Gen Enzyme Development For Sustainable API Manufacturing
4/3/2024
Prozomix, a UK-based biotech company focused on novel biocatalyst discovery and manufacturing, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership.
-
Ipsen And Sutro Biopharma Announce Exclusive Global Licensing Agreement For An ADC Targeting Solid Tumors
4/2/2024
Ipsen and Sutro Biopharma today announced an exclusive global licensing agreement for STRO-003. STRO-003, an antibody-drug conjugate (ADC) in the final stages of pre-clinical development, targets the ROR1 tumor antigen which is known to be overexpressed in many different cancer types including solid tumors and hematological malignancies.1
-
Blue Wolf Capital To Acquire OSD CDMO Sites From Recipharm
4/2/2024
Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the healthcare and industrial sectors, announced today that it has committed, subject to regulatory clearances, to acquire seven manufacturing and development facilities: Solna, Stängnäs, Höganäs, Karlskoga and Uppsala OTC Development in Sweden, Pessac in France, and Parets in Spain, from Recipharm, a contract development and manufacturing organization (“CDMO”) headquartered in Stockholm.
-
BioInvent Announces A New Clinical Trial Collaboration And Supply Agreement With MSD To Evaluate BI-1910, The Company’s Second Anti-TNFR2 Antibody In Combination With KEYTRUDA (pembrolizumab)
4/2/2024
BioInvent International AB (“BioInvent”) a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces a clinical trial collaboration and supply agreement with MSD International Business GmbH, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, for a Phase 1/2a study of its monoclonal antibody BI-1910 in combination with KEYTRUDA (pembrolizumab).
-
Invenra Inc. Announces A Strategic Collaboration With Catalent To Co-Discover Novel Bispecific ADCs
4/2/2024
Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions.
-
Delpharm Continues Its Growth In Europe With The Acquisition Of State-Of-The-Art Drug Production Facilities In The Netherlands, From Astellas
4/2/2024
The site, fully equipped with state-of-the-art technologies, is located in the Netherlands in a 31,600 square meter unit created in 1994.
-
Aterian Investment Partners To Recapitalize CPL, A Leading Pharmaceutical Contract Development And Manufacturing Organization
4/1/2024
Aterian Investment Partners (“Aterian”), a private investment firm, is pleased to announce that one of its affiliates has entered into an agreement to recapitalize Contract Pharmaceuticals Limited Canada ("CPL" or the “Company”), a leading North American contract development and manufacturing organization (CDMO) of non-sterile liquid and semi-solid dosage forms.
-
Bora Pharmaceuticals Completes The Acquisition Of Upsher-Smith
4/1/2024
Bora Pharmaceuticals Co., Ltd. today announced that it has successfully completed the acquisition of Upsher-Smith Laboratories, LLC (“Upsher-Smith”), a generics manufacturer and marketer based in Minnesota, U.S., from its sellers, Sawai Group Holdings and Sumitomo Corporation of Americas.